HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goss, J. R. Articles by Fink, D. J. Search for Related Content PubMed PubMed Citation Articles by Goss, J. R. Articles by Fink, D. J. Social Bookmarking                What's this?

Herpes Simplex-Mediated Gene Transfer of Nerve Growth Factor Protects Against Peripheral Neuropathy in Streptozotocin-Induced Diabetes in the Mouse

¹ Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
² Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
³ Geriatric Research Education and Clinical Center, VA Medical Center, Pittsburgh, Pennsylvania

Peripheral neuropathy is a common and debilitating complication of diabetes. In animal models, neurotrophic factors can prevent progression of the neuropathy, but adverse effects prevent systemic administration in adequate doses to treat human disease. We examined whether gene transfer with replication-defective genomic herpes simplex virus (HSV) vectors modified to express nerve growth factor (NGF) could be used to prevent progression of neuropathy in mice. Diabetes induced by streptozotocin (STZ) resulted in a sensory neuropathy manifest by a decrease in the foot sensory nerve amplitude (FSA; control = 20 ± 0.1 µV, treated = 14 ± 0.1 µV). Transduction of dorsal root ganglia in vivo with an HSV-based vector expressing NGF under the control of the human cytomegalovirus immediate early promoter (vector SHN) or the HSV latency active promoter 2 (vector SLN) by footpad inoculation 2 weeks after STZ administration protected against the decrease in FSA (22 ± 1.4 µV and 21 ± 1.7 µV, respectively) measured 4 weeks later. Injection of SHN into inguinal adipose tissue 2 weeks after onset of diabetes also prevented the decrease in FSA (20 ± 3.3 µV). These results suggest that gene transfer with an NGF-producing herpes-based vector may prove useful in the treatment of diabetic neuropathy.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Ieda, H. Kanazawa, Y. Ieda, K. Kimura, K. Matsumura, Y. Tomita, T. Yagi, T. Onizuka, K. Shimoji, S. Ogawa, et al. Nerve Growth Factor Is Critical for Cardiac Sensory Innervation and Rescues Neuropathy in Diabetic Hearts Circulation, November 28, 2006; 114(22): 2351 - 2363. [Abstract] [Full Text] [PDF]

				M. Nakae, H. Kamiya, K. Naruse, N. Horio, Y. Ito, R. Mizubayashi, Y. Hamada, E. Nakashima, N. Akiyama, Y. Kobayashi, et al. Effects of basic fibroblast growth factor on experimental diabetic neuropathy in rats. Diabetes, May 1, 2006; 55(5): 1470 - 1477. [Abstract] [Full Text] [PDF]

				N. Kato, K. Nemoto, K. Nakanishi, R. Morishita, Y. Kaneda, M. Uenoyama, T. Ikeda, and K. Fujikawa Nonviral Gene Transfer of Human Hepatocyte Growth Factor Improves Streptozotocin-Induced Diabetic Neuropathy in Rats Diabetes, March 1, 2005; 54(3): 846 - 854. [Abstract] [Full Text] [PDF]

				J. R. Mendell and A. Miller Gene transfer for neurologic disease: Agencies, policies, and process Neurology, December 28, 2004; 63(12): 2225 - 2232. [Abstract] [Full Text] [PDF]

				K. Sasaki, M. B. Chancellor, W. F. Goins, M. W. Phelan, J. C. Glorioso, W. C. de Groat, and N. Yoshimura Gene Therapy Using Replication-Defective Herpes Simplex Virus Vectors Expressing Nerve Growth Factor in a Rat Model of Diabetic Cystopathy Diabetes, October 1, 2004; 53(10): 2723 - 2730. [Abstract] [Full Text] [PDF]

				S M Selkirk Gene therapy in clinical medicine Postgrad. Med. J., October 1, 2004; 80(948): 560 - 570. [Abstract] [Full Text] [PDF]

				C. Jiang, J. B. Wechuck, W. F. Goins, D. M. Krisky, D. Wolfe, M. M. Ataai, and J. C. Glorioso Immobilized Cobalt Affinity Chromatography Provides a Novel, Efficient Method for Herpes Simplex Virus Type 1 Gene Vector Purification J. Virol., September 1, 2004; 78(17): 8994 - 9006. [Abstract] [Full Text] [PDF]

				C. Theopold, F. Yao, and E. Eriksson Gene Therapy in the Treatment of Lower Extremity Wounds International Journal of Lower Extremity Wounds, June 1, 2004; 3(2): 69 - 79. [Abstract] [PDF]

				M. Chattopadhyay, J. Goss, D. Wolfe, W. C. Goins, S. Huang, J. C. Glorioso, M. Mata, and D. J. Fink Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy Brain, April 1, 2004; 127(4): 929 - 939. [Abstract] [Full Text] [PDF]

				M. Mata, J. C. Glorioso, and D. J. Fink Gene Transfer to the Nervous System: Prospects for Novel Treatments Directed at Diseases of the Aging Nervous System J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2003; 58(12): M1111 - 1118. [Abstract] [Full Text] [PDF]

				T. C. Coste, A. Gerbi, P. Vague, G. Pieroni, and D. Raccah Neuroprotective Effect of Docosahexaenoic Acid-Enriched Phospholipids in Experimental Diabetic Neuropathy Diabetes, October 1, 2003; 52(10): 2578 - 2585. [Abstract] [Full Text] [PDF]